December 21, 2017 / 6:31 AM / in a year

Roche's Alecensa receives EU approval to treat ALK-positive lung cancer

ZURICH, Dec 21 (Reuters) - The European Commission has approved Roche's Alecensa as treatment for a form of lung cancer common in patients without a significant smoking history, the Swiss drug maker said on Thursday.

The market authorisation for adults with anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer follows a positive phase III study in which Alecensa was shown to reduce the risk of disease progression or death by more than half versus crizotinib, a chemotherapy developed by Pfizer.

The lung cancer in question commonly affects younger patients, with an average age of 52, with no or only a light smoking history. (Reporting by Brenna Hughes Neghaiwi)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below